Keith Woods

“As David noted, our team continues to operate with urgency as we prepare for the launch of EpidograMap. Our commercial organization remains focused and disciplined, advancing the critical capabilities required to deliver a seamless launch and support patients from day one.”

“While I'm very much looking forward to this next phase, spending more time with my family, and transitioning to an advisory role for argenx, it was still a difficult decision to make.”

“Slide 10, we are very happy with the continued momentum this quarter with our VYVGART launch, driven by consistent growth in both patient and physician demand. The first six months of the launch are crucial in building the right foundation for the product.”

“To echo Tim's earlier comments, we are excited about the strong start we've had in the first quarter with regard to our commercial efforts. Our progress reflects both the benefit of our strategic preparation and the hard work and dedication of our experienced team.”

“I’m happy to provide an update on the state of our commercial business. Our salesforce has been in the field for eight weeks now, so we are still in the very early stages.”